Disease on EC 3.1.26.13 - retroviral ribonuclease H
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE 
TITLE OF PUBLICATION
LINK TO PUBMED
Acquired Immunodeficiency Syndrome
Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase.
Acquired Immunodeficiency Syndrome
Recent Advances in the Research of HIV-1 RNase H Inhibitors.
Acquired Immunodeficiency Syndrome
Recombinant polypeptides from the human immunodeficiency virus reverse transcriptase define three epitopes recognized by antibodies in sera from patients with acquired immunodeficiency syndrome.
Acquired Immunodeficiency Syndrome
Species differences in nucleotide pool levels of 2',3'-dideoxycytidine: a possible explanation for species-specific toxicity.
Acquired Immunodeficiency Syndrome
Ultrastructure of peripheral neuropathy induced in rabbits by 2',3'-dideoxycytidine.
Anemia
Purification and characterization of recombinant equine infectious anemia virus reverse transcriptase.
Anemia
Substituting a conserved residue of the ribonuclease H domain alters substrate hydrolysis by retroviral reverse transcriptase.
Equine Infectious Anemia
Purification and characterization of recombinant equine infectious anemia virus reverse transcriptase.
Equine Infectious Anemia
Substituting a conserved residue of the ribonuclease H domain alters substrate hydrolysis by retroviral reverse transcriptase.
Hepatitis B
HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients.
Infections
A Single Dose of a MIV-150/Zinc Acetate Gel Provides 24?h of Protection Against Vaginal Simian Human Immunodeficiency Virus Reverse Transcriptase Infection, with More Limited Protection Rectally 8-24?h After Gel Use.
Infections
Short communication: a repeated simian human immunodeficiency virus reverse transcriptase/herpes simplex virus type 2 cochallenge macaque model for the evaluation of microbicides.
Leukemia
Abortive reverse transcription by mutants of Moloney murine leukemia virus deficient in the reverse transcriptase-associated RNase H function.
Leukemia
Human immunodeficiency virus reverse transcriptase ribonuclease H: specificity of tRNA(Lys3)-primer excision.
Leukemia
Inhibition of human immunodeficiency virus-associated reverse transcriptase by 14-O-acyladriamycins.
Leukemia
Mechanisms of the inhibition of reverse transcription by antisense oligonucleotides.
Leukemia
RNase H domain of Moloney murine leukemia virus reverse transcriptase retains activity but requires the polymerase domain for specificity.
Leukemia
Sequence requirements for removal of tRNA by an isolated human immunodeficiency virus type 1 RNase H domain.
Leukemia
Specificity of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H in removal of the minus-strand primer, tRNA(Lys3).
Leukemia, T-Cell
Human T-cell leukemia virus type 1 reverse transcriptase (RT) originates from the pro and pol open reading frames and requires the presence of RT-RNase H (RH) and RT-RH-integrase proteins for its activity.
Neoplasms
Role of altered metabolism in dideoxynucleoside pharmacokinetics. Studies of 2'-beta-fluoro-2',3'-dideoxyinosine and 2'-beta-fluoro-2',3'-dideoxyadenosine in rats.
Neoplasms
Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones.
Visna
Treatment of visna virus infection in lambs with the acyclic nucleoside phosphonate analogue 9-(2-phosphonylmethoxyethyl)adenine (PMEA).
html completed
